

Effekt av HPV-vaksine i Livmorhalsprogrammet



Ameli Tropé

Leder for Livmorhalsprogrammet


Potensielle interessekonflikter

- Har ikke mottatt forskningsstøtte eller andre goder fra noe medisinsk firma
- Samarbeider med forskere på Kreftregisteret som har mottatt forskningsmidler fra MSD for HPV-vaksinestudier

Utvikling av livmorhalskreft




HPV-vaksiner i Norge



Vaksinasjon i Norge

25 år i 2022




HPV-vaksinasjondekning



Norway

National schedule	Year of introduction	Delivery strategy	Targeted Age	Targeted Sex	Schedule (interval between doses)
Yes	2009	School-based	12	Both sexes	2 doses (6 months)


HPV vaccine, programme coverage in female





Kvinner 25-69: 1 566 474

*Kilde: Statistisk Sentralbyrå



HPV-test: 404 474



Cytologi: 203 168



Histologi: 48 970



Konseringer: 7 200



Kreft: 325



Døde: 80


*Kilde: Dødsårsaksregisteret



Livmorhals
programmet


2023

Antall krefttilfeller diagnostisert blant kvinner 25 år





Ikke publiserte tall Krefregisteret

CIN3+/antall screenede kvinner, 25 år




Screening og utredning når forekomst av CIN3 er lavere




HPV Type	Species	% in Cancer	% in Normal	Odds Ratio	% Attributable Fraction
HPV16	a9	55.8	2.6	47.6	62.4
HPV18	a7	14.3	1	15.7	15.3
HPV45	a7	4.8	0.6	8.3	4.8
HPV33	a9	4	0.6	7.1	3.9
HPV58	a9	4	0.8	5.1	3.7
HPV31	a9	3.5	1	3.7	2.9
HPV52	a9	3.2	1	3.3	2.6
HPV35	a9	1.6	0.4	3.9	1.4
HPV59	a7	1.2	0.4	2.9	0.9
HPV39	a7	1.3	0.6	2.0	0.8
HPV68	a7	0.6	0.4	1.5	0.2
HPV51	a5	1	0.9	1.2	0.2
HPV56	a6	0.8	0.6	1.3	0.2
HPV73	a11	0.5	0.3	1.8	0.2
HPV26	a5	0.2	0.1	4.1	0.2
HPV30	a6	0.2	0.1	2.6	0.1
HPV69	a5	0.2	0.1	1.4	0.1
HPV67	a9	0.3	0.2	1.2	<0.1
HPV82	a5	0.2	0.1	1.2	<0.1
HPV34	a11	0.1	0.1	1.0	Not attributable
HPV66	a6	0.3	0.6	0.4	Not attributable
HPV70	a7	0.2	0.8	0.3	Not attributable
HPV53	a6	0.5	1.1	0.4	Not attributable

Attributable fraction cervical cancer



Combes et al, IJC 2014
IARC Handbook of Cervical
Cancer Prevention

Sammenligning av antallet screeningrunder og totalkostnader ved bruk av 2-valent og 9-valent HPV-vaksine for å forebygge 480 dødsfall av livmorhalskreft i hvert årskull



Takk

